1.Nakashima M, Morita J, Aizawa K. Pharamacokinetics and safety of tebipenem pivoxil fine granules, an oral carbapenem antibiotic, in healthy male volunteers. Jpn J Chemother. 2009;57(S–1):90–94 2.Baba S, Yamanaka N, Suzuki K, et al. Clinical efficacy, safety and PK-PD analysis of tebipenem pivoxil in a phase II clinical trial in otolaryngological infections. Jpn J Antibiot. 2009;62:155–177 3.Sunakawa K. Pharmacological properties and clinical performance of the novel oral carbapenem antimicrobial drug, “Tebipenem pivoxil” (Orapenem fine granules 10% for pediatric use). Jpn J Chemother. 2009;57:279–294 4.Yamanaka N, Furukawa M, Furuya, et al. Clinical efficacy of tebipenem pivoxil (ME1211), a novel oral carbapenem, in otolaryngological infections, a Phase II clinical trial (1). 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) 2005; Abstract L-577 5.Iwata S, Ouchi K, Iwata N, et al. An open clinical study of tebipenem pivoxil in children with bacterial pneumonia. Jpn J Chemother. 2009;57(S–1):137–150   [更多]

1.丙氨酰谷氨酰胺及其注射液的研究開(kāi)發(fā) 2.A prospective multicentre study on the treatment of cardiovascular risk factors and claudication symptoms in patients with peripheral artery disease (the IDOMENEO study). Cimminiello C, Arpaia G, Polo Friz H, Boracchi P, Marano G, Spezzigu G, Visonà A. Vasa. 2015 Sep;44(5):371-9. doi: 10.1024/0301-1526/a000456. 3.2013 International Conference on Materials Engineering, ICMEN 2013 4.Orientation of substitution in the aromatic series. XVIII. Sulfonation of phenol by chlorosulfonic acid in solvents 5.Mechanism of reaction of chlorosulfonic acid with some aromatic compounds 6.Arzneimittelforschung. 1982;32(3):248-51. In vitro--in vivo correlation, a time scaling problem? Basic considerations on in vitro dissolution testing. 7.Oral treatment with the Crataegus special extract WS 1442 inhibits cardiac hypertrophy in rats with DOCA-salt or aortic banding induced hypertension   [更多]

1.Nihon Yakurigaku Zasshi. 2013 Jul;142(1):39-46. doi: 10.1254/fpj.142.39. Pharmacological and clinical properties of AIMIX combination tablets LD&HD, fixed-dose combination of irbesartan and amlodipine besilate. 2.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 3.Clin Ther. 2012 Aug;34(8):1705-19. doi: 10.1016/j.clinthera.2012.06.026. Epub 2012 Jul 30. I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 4.Clin Ther. 2012 Aug;34(8):1720-34.e3. doi: 10.1016/j.clinthera.2012.07.001. Epub 2012 Jul 30. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 5.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 6J Cardiol. 2019 Mar 20. pii: S0914-5087(19)30053-X. doi: 10.1016/j.jjcc.2019.03.001. [Epub ahead of print] Arginine vasopressin antagonism in heart failure: Current status and possible new directions. Goldsmith SR1. 7.Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability 8.Expert Rev Neurother. 2017 Jan;17(1):59-75. Epub 2016 Oct 20. Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology. Tramutola A1, Arena A1,   [更多]

求購(gòu)“Saccharin Sodium” BP2017 和BP2018的藥典標(biāo)準(zhǔn)各一份   [更多]

簡(jiǎn)介：藥智人才是最專(zhuān)業(yè)的醫(yī)藥產(chǎn)業(yè)招聘平臺(tái)，與許多醫(yī)藥行業(yè)的知名企業(yè)都有合作，職位種類(lèi)豐富，崗位更專(zhuān)業(yè)~ 賺取賞金規(guī)則（活動(dòng)時(shí)間：5月13日-5月17日）： 1.免費(fèi)注冊(cè)/登錄藥智人才（https://job.yaozh.com/），上傳簡(jiǎn)歷： 簡(jiǎn)歷完善度≥80 可獲得50元賞金； 2.簡(jiǎn)歷完成后，并截圖藥智人才簡(jiǎn)歷板塊的完善度提交審核，并且備注藥智人才的用戶(hù)名/注冊(cè)手機(jī)信息； 3.審核通過(guò)后，賞金會(huì)在3個(gè)工作日內(nèi)審核并發(fā)放，如提交后有刪除簡(jiǎn)歷的行為，視為作弊處理，對(duì)應(yīng)賞金將會(huì)被凍結(jié)不予提現(xiàn)。 4.特別福利：簡(jiǎn)歷完善后既有機(jī)會(huì)直接內(nèi)推給名企噢~ 溫馨提示： 1.如果疑問(wèn)可以聯(lián)系客服QQ：3413833812 2.一經(jīng)發(fā)現(xiàn)求職者在上傳簡(jiǎn)歷期間有作弊等行為，藥智人才將取消其賞金并凍結(jié)該筆提現(xiàn)。 3.在法律允許的范圍內(nèi)，本活動(dòng)一切解釋權(quán)歸藥智人才 下期活動(dòng)預(yù)告 活動(dòng)日期：5月20-5月24日 賞金金額：更多賺取賞金細(xì)則5月20日揭曉噢~   [更多]

本人畢業(yè)論文要用到一些數(shù)據(jù)，需要一份截止目前為止的國(guó)內(nèi)藥品申請(qǐng)專(zhuān)利的數(shù)量和類(lèi)型匯總（可專(zhuān)利點(diǎn)），然后這些申請(qǐng)成功的藥品之中已經(jīng)成功上市的專(zhuān)利數(shù)量匯總（成功轉(zhuǎn)化成商品，應(yīng)用到藥企的專(zhuān)利），就是簡(jiǎn)單做個(gè)數(shù)據(jù)分析，分析我國(guó)的藥品專(zhuān)利商品化率，最好是有一些數(shù)據(jù)，如果有表格要做成三線(xiàn)表格，如果可以要和同期的國(guó)外藥品轉(zhuǎn)化率作對(duì)比，然后數(shù)據(jù)需要標(biāo)注一下數(shù)據(jù)的來(lái)源，有參考文獻(xiàn)要備注參考文獻(xiàn)，要盡快完成，謝謝~   [更多]

求購(gòu)左氧氟沙星EP9.8版 需要是PDF可以復(fù)制版 多謝   [更多]

中國(guó)藥典第一部英文版   [更多]

需要PDF可以復(fù)制版，謝謝。   [更多]

求購(gòu)“Trometamol”《BP2019》的藥典標(biāo)準(zhǔn)一份.   [更多]